A cloud of doubt hanging over the company just gave way to some sunshine. Shares of Novavax (NVAX 96.20%) are up 12% as of midday Friday following the release of the drugmaker's first-quarter results. It's not the report, however, driving the bulk of today's oversize gain -- it's the announcement made in conjunction with it. The company is partnering with fellow pharmaceutical company Sanofi (SNY 0.90%) to market Novavax's COVID vaccine. The deal also opens the door to the development of a flu vaccine based ...

Novavax (NASDAQ:NVAX) stock investors are celebrating on Friday as the vaccine company’s shares hit a new 52-week high after announcing a deal with Sanofi (NASDAQ:SNY). This saw shares of NVAX stock climb as high as $9.22 per share during normal trading hours on Friday. That comes with some 142 million shares of the stock changing hands. For the record, this is well above its daily average of about 6.8 million shares. Investors will note that NVAX stock hasn’t been in this range since September 2022. Howeve ...

Novavax (NASDAQ:NVAX) stock has more than doubled today and is up more than 120% at the time of this writing. This morning, the company announced a co-exclusive licensing agreement with Sanofi (NASDAQ:SNY) to commercialize its Covid-19 vaccine. The agreement will also provide Sanofi with a sole license to the vaccine for use in combination with its flu vaccines. On top of that, Sanofi will receive “a non-exclusive license to use Novavax’s adjuvanted COVID-19 vaccine for use in combination with non-flu vacci ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government. S ...

Key Takeaways Novavax shares more than doubled in intraday trading Friday as it announced a $1.2 billion deal to license its vaccine technology to Sanofi. Novavax will co-commercialize its COVID-19 vaccine with the French drugmaker, along with developing others like a combination COVID-19 and flu vaccine. The vaccine maker also announced first-quarter results that included a wider-than-expected net loss. Novavax (NVAX) shares more than doubled in intraday trading Friday after announcing a $1.2 billion deal ...

Forbes Community Guidelines Our community is about connecting people through open and thoughtful conversations. We want our readers to share their views and exchange ideas and facts in a safe space. In order to do so, please follow the posting rules in our site's Terms of Service. We've summarized some of those key rules below. Simply put, keep it civil. Your post will be rejected if we notice that it seems to contain: False or intentionally out-of-context or misleading information Spam Insults, profanity, ...

Exhibit 99.1 Press Release Novavax Reports First Quarter 2024 Financial Results and Operational Highlights · Announces co-exclusive licensing agreement with Sanofi to co-commercialize COVID-19 vaccine, develop novel COVID-19- Influenza combination vaccines and develop multiple new vaccines utilizing Novavax’s Matrix-M adjuvant · This agreement represents a potential multi-billion dollar revenue opportunity for Novavax including: o $500 million upfront payment o Approximately $70 million equity investment in ...

Novavax (NVAX) came out with a quarterly loss of $1.05 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to loss of $3.41 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -0.96%. A quarter ago, it was expected that this vaccine maker would post a loss of $0.49 per share when it actually produced a loss of $1.44, delivering a surprise of -193.88%. Over the last four quarters, the company has surpas ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 000-26770 NOVAVAX, INC. (Exact name of registrant as specified in its charter) Delaware 22-2816046 (State or other jurisdictio ...

Follow Invezz on Telegram , Twitter , and Google News for instant updates > Novavax (NASDAQ:NVAX) shares rocketed 40% in premarket trading Friday, driven not only by the company’s fiscal Q1 2024 earnings report but more significantly, by a crucial multi-billion dollar deal with French pharmaceutical giant Sanofi SA. Are you looking for signals & alerts from pro-traders? Sign-up to Invezz Signals™ for FREE. Takes 2 mins. Despite reporting a first-quarter loss per share of $1.05, wider than the $0.92 anticipa ...